CA3250387A1 - Tetrahydropyrido[3,4-D]pyrimidine compounds used as HPK1 inhibitors - Google Patents

Tetrahydropyrido[3,4-D]pyrimidine compounds used as HPK1 inhibitors

Info

Publication number
CA3250387A1
CA3250387A1 CA3250387A CA3250387A CA3250387A1 CA 3250387 A1 CA3250387 A1 CA 3250387A1 CA 3250387 A CA3250387 A CA 3250387A CA 3250387 A CA3250387 A CA 3250387A CA 3250387 A1 CA3250387 A1 CA 3250387A1
Authority
CA
Canada
Prior art keywords
mmol
group
hydrogen
pct
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3250387A
Other languages
English (en)
French (fr)
Inventor
Momar TOURE
Bin Li
Constantin Neagu
Yanping Wang
Theresa Johnson
Andrea UNZUE LOPEZ
Yufang Xiao
Emily FRIIS
Maria DIPOTO
Satenig Guler
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA3250387A1 publication Critical patent/CA3250387A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3250387A 2022-05-10 2023-05-04 Tetrahydropyrido[3,4-D]pyrimidine compounds used as HPK1 inhibitors Pending CA3250387A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263340191P 2022-05-10 2022-05-10
US63/340,191 2022-05-10
US202263383190P 2022-11-10 2022-11-10
US63/383,190 2022-11-10
PCT/US2023/066601 WO2023220541A1 (en) 2022-05-10 2023-05-04 Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors

Publications (1)

Publication Number Publication Date
CA3250387A1 true CA3250387A1 (en) 2023-11-16

Family

ID=86688794

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3250387A Pending CA3250387A1 (en) 2022-05-10 2023-05-04 Tetrahydropyrido[3,4-D]pyrimidine compounds used as HPK1 inhibitors

Country Status (9)

Country Link
US (1) US20240025922A1 (enExample)
EP (1) EP4522618A1 (enExample)
JP (1) JP2025521083A (enExample)
CN (1) CN119546610A (enExample)
AU (1) AU2023267747A1 (enExample)
CA (1) CA3250387A1 (enExample)
IL (1) IL316818A (enExample)
TW (1) TW202400612A (enExample)
WO (1) WO2023220541A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025210407A1 (en) * 2024-04-01 2025-10-09 Merck Patent Gmbh (7-{1h,2h,3h-pyrido [2,3-b][1,4]oxazin-7-yl}-5h,6h,7h,8h-pyrido[3,4-d]pyrimidin-2-yl)amine derivatives as bifunctional degraders of hpk1 for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019010302A (es) * 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.

Also Published As

Publication number Publication date
TW202400612A (zh) 2024-01-01
AU2023267747A1 (en) 2024-11-07
JP2025521083A (ja) 2025-07-08
IL316818A (en) 2025-01-01
WO2023220541A1 (en) 2023-11-16
CN119546610A (zh) 2025-02-28
US20240025922A1 (en) 2024-01-25
EP4522618A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
AU2019240299B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
US10828290B2 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
TWI808955B (zh) 作為免疫調節劑之雜環化合物
AU2018243770A1 (en) Isoquinolines as inhibitors of HPK1
TW201100429A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US20240109900A1 (en) Azabicyclic shp2 inhibitors
JP2023534837A (ja) アンドロゲン受容体モジュレーターとしてのインドール化合物
EP4313983A1 (en) (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo [1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer
AU2023267747A1 (en) Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors
TW202440086A (zh) 作為激酶抑制劑之雙環脲
WO2024153077A1 (zh) Hpk1抑制剂及其制法和用途
HK40093304A (en) Pyridinecarboxamide compound useful as pim kinase inhibitor
EA039704B1 (ru) Тиазолкарбоксамиды и пиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
HK1216424B (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241023

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241205

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241205

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241205

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250422

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250422

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260421

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260421